These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18822183)

  • 41. Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl
    Fujimoto M; Kito H; Kajikuri J; Ohya S
    Cancer Sci; 2018 Sep; 109(9):2781-2791. PubMed ID: 29949674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphorylation and changes in the distribution of nucleolin promote tumor metastasis via the PI3K/Akt pathway in colorectal carcinoma.
    Wu DM; Zhang P; Liu RY; Sang YX; Zhou C; Xu GC; Yang JL; Tong AP; Wang CT
    FEBS Lett; 2014 May; 588(10):1921-9. PubMed ID: 24713430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells.
    Kang JH; Krause S; Tobin H; Mammoto A; Kanapathipillai M; Ingber DE
    Lab Chip; 2012 Jun; 12(12):2175-81. PubMed ID: 22453808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.
    Mei XL; Zhong S
    Chin Med J (Engl); 2019 Feb; 132(4):454-465. PubMed ID: 30707166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
    Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs.
    Nejatollahi F; Ranjbar R; Younesi V; Asgharpour M
    Oncol Res; 2013; 20(8):333-40. PubMed ID: 23924853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.
    Safdari Y; Khalili M; Ebrahimzadeh MA; Yazdani Y; Farajnia S
    Pharmacol Res; 2015 Mar; 93():1-10. PubMed ID: 25533812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection.
    Hager G; Cacsire-Castillo Tong D; Schiebel I; Rezniczek GA; Watrowski R; Speiser P; Zeillinger R
    Gynecol Oncol; 2005 Aug; 98(2):211-6. PubMed ID: 15967487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients.
    Seow HF; Yip WK; Loh HW; Ithnin H; Por P; Rohaizak M
    Pathol Oncol Res; 2010 Jun; 16(2):239-48. PubMed ID: 19882362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR-rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway-suppressed ROS.
    Li F; Zhao X; Sun R; Ou J; Huang J; Yang N; Xu T; Li J; He X; Li C; Yang M; Zhang Q
    J Extracell Vesicles; 2020 Oct; 10(1):e12003. PubMed ID: 33304472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
    Saglam O; Husain S; Toruner G
    Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cadmium promotes the proliferation of triple-negative breast cancer cells through EGFR-mediated cell cycle regulation.
    Wei Z; Song X; Shaikh ZA
    Toxicol Appl Pharmacol; 2015 Nov; 289(1):98-108. PubMed ID: 26385184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "The Infinite Maze" of breast cancer, signaling pathways and radioresistance.
    Kaidar-Person O; Lai C; Kuten A; Belkacemi Y;
    Breast; 2013 Aug; 22(4):411-8. PubMed ID: 23642528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer.
    Lin HJ; Hsieh FC; Song H; Lin J
    Br J Cancer; 2005 Dec; 93(12):1372-81. PubMed ID: 16288304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.
    Hu H; Goltsov A; Bown JL; Sims AH; Langdon SP; Harrison DJ; Faratian D
    Cell Signal; 2013 Jan; 25(1):26-32. PubMed ID: 23000339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
    She QB; Chandarlapaty S; Ye Q; Lobo J; Haskell KM; Leander KR; DeFeo-Jones D; Huber HE; Rosen N
    PLoS One; 2008 Aug; 3(8):e3065. PubMed ID: 18725974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
    Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan LX; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi GN; Michiels S; Delaloge S; Esteva FJ
    Ann Oncol; 2008 Feb; 19(2):315-20. PubMed ID: 17804473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MUC1 induces the accumulation of Foxp3
    Zhang G; Zheng G; Zhang H; Qiu L
    Int Immunopharmacol; 2023 May; 118():110091. PubMed ID: 37018979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiation-induced EGFR-signaling and control of DNA-damage repair.
    Rodemann HP; Dittmann K; Toulany M
    Int J Radiat Biol; 2007; 83(11-12):781-91. PubMed ID: 18058366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function.
    Folgiero V; Bachelder RE; Bon G; Sacchi A; Falcioni R; Mercurio AM
    Cancer Res; 2007 Feb; 67(4):1645-52. PubMed ID: 17308105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.